New adaptive method for phase I trials in oncology

Area of Science:

• Oncology
• Clinical Trial Design
• Biostatistics

Background:

• Phase I oncology trials aim to determine the maximum tolerated dose (MTD) in small patient cohorts.
• Current methods for MTD assessment can be time-consuming and may not fully account for individual patient variability.

Purpose of the Study:

• To develop and evaluate a new adaptive approach for efficient MTD assessment in phase I oncology trials.
• To integrate toxicity differentiation, dose-limiting toxicity definition, risk modeling, and covariate analysis for personalized MTD determination.

Main Methods:

• Proposed an adaptive statistical framework incorporating toxicity grading and logical combinations for dose-limiting toxicity.
• Developed a risk model linking toxic events to drug dose and integrated individual patient covariates.
• Applied the approach to retrospective data from a pediatric Taxol trial and conducted simulation studies.

Main Results:

• Identified age as a significant covariate, enabling individualized MTD in the Taxol pediatric trial.
• Simulation studies demonstrated efficient patient enrollment, dose-finding constraints, and trial stopping rules.
• The novel approach facilitates rapid MTD assessment even with limited patient numbers.

Conclusions:

• The proposed adaptive method enhances the precision and speed of MTD determination in phase I oncology trials.
• Individualizing MTD based on patient covariates like age improves trial design and patient safety.
• This approach offers a valuable tool for optimizing early-phase cancer drug development.